Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBELICS: Bevacizumab Optimization in mCRC
NCT01718873Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started May 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01718873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718873.